Scrip
Savient to raise $53 million to fund gout treatment approval
09 October 2009
Eleanor Malone
Please Login to read the full article.
09 October 2009
Eleanor Malone
Savient Pharmaceuticals expects to raise $52.9 million in net proceeds from a share offering, which it will use partly to fund efforts to gain FDA approval for its gout therapy Krystexxa (pegloticase). It is selling 4.3 million shares of common stock priced at $13.29 per share, and has granted its...
Please Login to read the full article.
RELATED CONTENT
COMMENT
Other Informa Comment
FEATURES
- Dr Jonathan Knowles: Roche's passionate visionary
- Recipharm sees opportunity to ride wave of CDMO consolidation
EVENTS
Today
Berlin, Germany
Today
Berlin, Germany
22 March 2010
London, UK
JOB OF THE WEEK
Promote your vacancy here
DIRECTORY
Scrip Directory 2009
